As of 2024-12-14, the EV/EBITDA ratio of BioCryst Pharmaceuticals Inc (BCRX) is -58.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BCRX's latest enterprise value is 2,295.87 mil USD. BCRX's TTM EBITDA according to its financial statements is -39.34 mil USD. Dividing these 2 quantities gives us the above BCRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing P/E multiples | 15.1x - 18.6x | 16.6x |
Forward P/E multiples | 15.3x - 26.1x | 20.2x |
Fair Price | (6.46) - (7.08) | (7.05) |
Upside | -185.8% - -194.0% | -193.7% |
Date | EV/EBITDA |
2024-12-06 | -58.78 |
2024-12-05 | -59.99 |
2024-12-04 | -57.30 |
2024-12-03 | -56.57 |
2024-12-02 | -57.57 |
2024-11-29 | -58.20 |
2024-11-27 | -58.20 |
2024-11-26 | -58.14 |
2024-11-25 | -56.99 |
2024-11-22 | -58.72 |
2024-11-21 | -58.14 |
2024-11-20 | -57.14 |
2024-11-19 | -56.67 |
2024-11-18 | -55.88 |
2024-11-15 | -55.72 |
2024-11-14 | -57.93 |
2024-11-13 | -58.93 |
2024-11-12 | -59.88 |
2024-11-11 | -61.83 |
2024-11-08 | -59.67 |
2024-11-07 | -59.09 |
2024-11-06 | -59.41 |
2024-11-05 | -55.85 |
2024-11-04 | -57.41 |
2024-11-01 | -63.09 |
2024-10-31 | -60.88 |
2024-10-30 | -62.78 |
2024-10-29 | -61.46 |
2024-10-28 | -61.62 |
2024-10-25 | -60.57 |
2024-10-24 | -61.78 |
2024-10-23 | -61.15 |
2024-10-22 | -60.57 |
2024-10-21 | -58.30 |
2024-10-18 | -58.83 |
2024-10-17 | -58.14 |
2024-10-16 | -58.57 |
2024-10-15 | -58.09 |
2024-10-14 | -57.99 |
2024-10-11 | -57.83 |
2024-10-10 | -56.20 |
2024-10-09 | -56.88 |
2024-10-08 | -56.62 |
2024-10-07 | -57.88 |
2024-10-04 | -58.62 |
2024-10-03 | -57.78 |
2024-10-02 | -57.57 |
2024-10-01 | -57.57 |
2024-09-30 | -58.72 |
2024-09-27 | -58.83 |